Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Discovery and development of aurora kinase inhibitors as anticancer agents.

× No keyword cloud information.

43 in total

1. Activation of Aurora-A kinase by protein partner binding and phosphorylation are independent and synergistic.

Authors: Charlotte A Dodson; Richard Bayliss
Journal: J Biol Chem Date: 2011-11-16 Impact factor: 5.157

2. An integrated pharmacokinetic-pharmacodynamic model for an Aurora kinase inhibitor.

Authors: Hiroko Kamei; Robert C Jackson; Daniella Zheleva; Fordyce A Davidson
Journal: J Pharmacokinet Pharmacodyn Date: 2010-08-08 Impact factor: 2.745

3. Some insights into the binding mechanism of Aurora B kinase gained by molecular dynamics simulation.

Authors: Rui Xiong; Xiao-Mei Cai; Jing Wei; Peng-Yu Ren
Journal: J Mol Model Date: 2012-05-30 Impact factor: 1.810

4. Identification of Myb-binding protein 1A (MYBBP1A) as a novel substrate for aurora B kinase.

Authors: Claudia Perrera; Riccardo Colombo; Barbara Valsasina; Patrizia Carpinelli; Sonia Troiani; Michele Modugno; Laura Gianellini; Paolo Cappella; Antonella Isacchi; Jurgen Moll; Luisa Rusconi
Journal: J Biol Chem Date: 2010-02-22 Impact factor: 5.157

Review 5. Learning about cancer from frogs: analysis of mitotic spindles in Xenopus egg extracts.

Authors: Marie K Cross; Maureen A Powers
Journal: Dis Model Mech Date: 2009 Nov-Dec Impact factor: 5.758

6. The molecular mechanism studies of chirality effect of PHA-739358 on Aurora kinase A by molecular dynamics simulation and free energy calculations.

Authors: Yuanhua Cheng; Wei Cui; Quan Chen; Chen-Ho Tung; Mingjuan Ji; Fushi Zhang
Journal: J Comput Aided Mol Des Date: 2011-01-11 Impact factor: 3.686

7. Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies.

Authors: Danielle C Chinn; William S Holland; Philip C Mack
Journal: J Cancer Res Clin Oncol Date: 2014-04-23 Impact factor: 4.553

Review 8. Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy.

Authors: Kinsie E Arnst; Souvik Banerjee; Hao Chen; Shanshan Deng; Dong-Jin Hwang; Wei Li; Duane D Miller
Journal: Med Res Rev Date: 2019-02-11 Impact factor: 12.944

9. Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors.

Authors: Matthew P Martin; Yunting Luo; Roberta Pireddu; Hua Yang; Harsukh Gevariya; Harshani R Lawrence; Sevil Ozcan; Jin-Yi Zhu; Robert Kendig; Mercedes Rodriguez; Roy Elias; Jin Q Cheng; Saïd M Sebti; Ernst Schonbrunn; Nicholas J Lawrence
Journal: J Med Chem Date: 2012-08-30 Impact factor: 7.446

10. Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.

Authors: Scott R Plotkin; Jaishri O Blakeley; D Gareth Evans; C Oliver Hanemann; Theo J M Hulsebos; Kim Hunter-Schaedle; Ganjam V Kalpana; Bruce Korf; Ludwine Messiaen; Laura Papi; Nancy Ratner; Larry S Sherman; Miriam J Smith; Anat O Stemmer-Rachamimov; Jeremie Vitte; Marco Giovannini
Journal: Am J Med Genet A Date: 2013-02-07 Impact factor: 2.802